Earnings Call Summary | Oncternal Therapeutics(ONCT.US) Q2 2024 Earnings Conference
Earnings Call Summary | Oncternal Therapeutics(ONCT.US) Q2 2024 Earnings Conference
Net loss for the quarter was $8.6 million, with a net loss per share of $2.89.The following is a summary of the Oncternal Therapeutics, Inc. (ONCT) Q2 2024 Earnings Call Transcript:
以下是Oncternal Therapeutics，Inc.（ONCT）2024年第二季度業績會議通話記錄摘要：
Financial Performance:
金融業績：
Oncternal reported grant revenue of $0.8 million for Q2 2024.
Total operating expenses for Q2 2024 were $9.7 million, with research and development accounting for $6.6 million, and general and administrative expenses totaling $3.1 million.
Net loss for the quarter was $8.6 million, with a net loss per share of $2.89.
The company has approximately $21.4 million in cash and equivalents, expecting to support operations into Q1 2025.
Oncternal報告2024年第二季度的授予收入爲$800,000。
2024年第二季度的總營業費用爲$9,700,000，研發費用爲$6,600,000，總行政費用爲$3,100,000。
本季度淨虧損爲$8,600,000，每股淨虧損爲$2.89。
該公司持有大約$21,400,000的現金及等價物，預計支持經營活動至2025年第一季度。
Business Progress:
業務進展：
ONCT-534, a dual-action androgen receptor inhibitor, is advancing in a Phase I/II study, with the sixth dosing cohort fully enrolled.
ONCT-808, an autologous CAR-T cell therapy targeting ROR1, is ongoing in a Phase I/II study for relapsed or refractory aggressive B-cell lymphoma.
ONCt-534是一種雙重作用雄激素受體抑制劑，正在進行第I/II期研究，第六個給藥隊列已招募滿員。
ONCt-808是一種自體CAR-t細胞療法，針對ROR1，正在進行第I/II期難治性或複發性侵襲性B細胞淋巴瘤(aggresive b-cell lymphoma)研究。
Opportunities:
機會：
Pending clinical updates and data readouts for ONCT-534 and ONCT-808 could potentially enhance Oncternal's portfolio and market position in cancer therapies.
在ONCt-534和ONCt-808的臨床更新和數據披露尚未公佈的情況下，很可能能夠提升Oncternal在癌症治療領域的產品組合和市場地位。
Risks:
風險：
The clinical advancement of ONCT-534 and ONCT-808 includes inherent risks tied to safety profile and efficacy outcomes, crucial for subsequent regulatory and development milestones.
ONCt-534和ONCt-808的臨床推進包括與安全概況相關的固有風險和對後續監管和發展里程碑至關重要的功效結果。
More details: Oncternal Therapeutics IR
更多詳情：Oncternal Therapeutics IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
